Warfarin therapy is feasible in CYP2C9*3 homozygous patients

European Journal of Internal Medicine

Volumn 15, Issue 1, 2004, Pages 22-27

  Ablin, Jacob ^a   Cabili, Shaltiel ^a   Eldor, Amiram ^a   Lagziel, Ayala ^b   Peretz, Hava ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

CYP2C9 polymorphism; Medication errors; Metabolic clearance rate; Pharmacogenetics

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C9; FIBRIC ACID DERIVATIVE; STATIN; WARFARIN;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; ENZYME DEFICIENCY; FEASIBILITY STUDY; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEREDITY; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; VALVULAR HEART DISEASE;

EID: 1842577785     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2003.10.004     Document Type: Article

References (27)

1. ASPECT (Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 26:1994;499-503.
2. Anand S., Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. J. Am. Med. Assoc. 282:1999;2058-2067.
3. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. New Engl. J. Med. 344:2001;1222-1231.
4. Bungard T.J., Ghali W.A., Teo K.K., McAlister F.A., Tsuyuki R.T. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med. 160:2000;41-46.
5. Miners J.O., Birkett D.J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45:1998;525-538.
6. Rettie A.E., Wienkers L.C., Gonzales F.J., Trager W.F., Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 4:1994;39-42.
7. Crespi C.L., Miller V.P. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 7:1997;203-210.
8. Takahashi H., Kashima T., Nomoto S., et al. Comparisons between in-vitro metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 8:1998;365-373.
9. Aithal G.P., Day C.P., Kesteven P.J.L., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719.
10. Ogg M., Brennan P., Meade T., Humphries S.E. CYP2C9*3 allelic variant and bleeding complications. Lancet. 354:1999;1124.
11. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 96:2000;1816-1819.
12. Margaglione M., Colaizzo D., D'Andrea G., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84:2000;775-778.
13. Steward D.J., Haining R.L., Henne K.R., et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 7:1997;361-367.
14. Brandolese R., Scordo M.G., Spina E., Gusella M., Parini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin. Pharmacol. Ther. 70:2001;391-394.
15. Ablin J., Cabili S., Lagziel A., Peretz H. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele. Isr. Med. Assoc. J. 4:2002;139-141.
16. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res. 16:1988;1215.
17. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349.
18. Loebstein R., Yonath H., Peleg D., et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70:2001;159-164.
19. Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J. Am. Med. Assoc. 287:2002;1690-1698.
20. Chu K., Wu S., Stanley T., Stafford D., High K. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J. Clin. Invest. 98:1996;1619-1625.
21. Mungall D.R., Ludden T.M., Marshall J., Hawkins D.W., Talbert R.L., Crawford M.H. Population pharmacokinetics of racemic warfarin in adult patients. J. Pharmacokinet. Biopharm. 13:1985;213-227.
22. Fihn S.D., Callahan C.M., Martin D.C., McDonell M.B., Henikoff J.G., White R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann. Intern. Med. 124:1996;970-979.
23. Wells P.S., Holbrook A.M., Crowther N.R., Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121:1994;676-683.
24. Bergman S.H. Medic drug interactions. 2000;21 Shirol Publications, Herzliya, Israel.
25. Tang C., Shou M., Mei Q., Rushmore T.H., Rodrigues A.D. Major role of human liver microsomal cytochrome P4502C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. 293:2000;453-459.
26. Aithal G.P., Day C.P., Leathart J.B., Daly A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics. 10:2000;511-518.
27. Thijssen H.H.W., Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin. Pharmacol. Ther. 74:2003;61-68.